Evidence map›Paper›PMID 33012892›Full record

ReviewColombia medica (Cali, Colombia)2020

COVID-19 and VIH.

María Paulina Posada-Vergara, Juan Carlos Alzate-Ángel, Ernesto Martínez-Buitrago

Open access · diamondAbstract readReview
In one paragraph

Review in Colombia medica (Cali, Colombia), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. HIV and COVID-19: review of clinical course and outcomes.HIV research & clinical practice · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

María Paulina Posada-VergaraGrupo VIHCOL, Cali, Colombia.ORCID 0000-0002-1516-1662
Juan Carlos Alzate-ÁngelGrupo VIHCOL, Cali, Colombia.ORCID 0000-0003-0319-0623
Ernesto Martínez-BuitragoGrupo VIHCOL, Cali, Colombia.ORCID 0000-0002-0959-8593
Corporación para Investigaciones Biológicas · COHospital Universitario del Valle ESE · COUniversidad Libre de Colombia · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Throughout the COVID-19 pandemic, the main risk factors associated with the progression to severe disease or death have been typically advanced age, diabetes mellitus, obesity, high blood pressure, heart disease, and chronic pneumopathy. Because of their immunosuppression status, persons with HIV were also expected to have a higher susceptibility to infection or a poor clinical evolution. So far, this has not been confirmed to happen, giving way to hypotheses about the role of immunosuppression or the use of antiretrovirals, which could explain this paradox. In this article we present the existing data on the epidemiology and characteristics of HIV-COVID-19 co-infection, discuss the available evidence on the possible factors involved in the evolution of individuals affected by both viruses, analyze other determinants that may negatively affect persons with HIV during the pandemic, and present recommendations for the prevention and care of COVID-19 infection in the context of HIV.

Indexed as

CoinfectionCoronavirus InfectionsCOVID-19Disease ProgressionHIV InfectionsHumansPandemicsPneumonia, ViralRisk FactorscoinfectionCOVID-19HIVSARS virus

Identifiers

PMID33012892
PMCPMC7518728
OpenAlexW3042346586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.